S. Galderisi, Italy

Professor of Psychiatry at the University of Campania Luigi Vanvitelli, Naples, Italy & Past President of the European Psychiatric Association Department of Psychiatry
Silvana Galderisi, MD, PhD, is full professor of Psychiatry, Chair of the Department of Mental and Physical Health and Preventive Medicine of the University of Campania Luigi Vanvitelli. She is the Director of the Emergency Unit of the Department of Mental Health of the same University; Coordinator of the Outpatient Unit for Anxiety and Psychotic Disorders and of the Rehabilitation Program for severe mental disorders of the same Department. She is President Elect of the Italian Society for Psychopathology (SOPSI), immediate Past President of the European Psychiatric Association (EPA), Chairperson of the EPA Schizophrenia Section, Co-chair of the Taskforce “Minimising coercion in mental health care” and member of the Standing Committee on Ethics of the World Psychiatric Association (WPA). She is founding member and member of the Board of Directors of the European Group for Research in Schizophrenia; Chairperson of the Communications Committee of the Schizophrenia International Research Society (SIRS), and member of the Strategic Plan Task Force of the same Association; board member of the European Scientific Association on Schizophrenia (ESAS), and of the Italian Society for Psychopathology and Italian Society of Biological Psychiatry. She is Honorary Fellow of the World Psychiatric Association-WPA, Honorary Member of the Polish Psychiatric Association and of the Hungarian Psychiatric Association (HPA), International Distinguished Fellow of the American Psychiatric Association-APA, International Advisor of the Japanese Society of Psychiatry and Neurology (JSPN), and Honorary Fellow of the European Society of Social Psychiatry (ESSP). Her research activity focuses on Schizophrenia pathophysiology, treatment and outcome, with particular reference to the domains of negative symptoms and cognition and their impact on psychosocial outcome. She is author/coauthor of more than 250 publications, in national and international journals and books, member of the Editorial Boards of several international psychiatric journals, Editor in Chief of Schizophrenia Bulletin Open.

Moderator Of 7 Sessions

Industry Session
Date
Sun, 11.04.2021
Session Time
13:30 - 14:30
Room
Industry 1
Session Description
Meeting the challenges of schizophrenia care during the COVID-19 pandemic - SUPPORTED BY Janssen

Session Description:

EPA 2021 Janssen-sponsored satellite symposium online summary:

This symposium will provide delegates with expert perspectives on optimum schizophrenia management under the challenging conditions of the COVID-19 pandemic. The session will examine considerations for maintenance treatment and long-term care, optimisation of the multidisciplinary team approach to schizophrenia care, and balancing caring for both the mental and physical health of patients with schizophrenia. Topics will include the use of telemedicine in schizophrenia management, recommendations for delivering optimum treatment continuity under social distancing conditions, and the pros and cons of monitoring schizophrenia treatment adherence and outcomes in person as well as through alternative monitoring approaches. In addition, the changes in exposure to antipsychotic medication in patients with schizophrenia during the pandemic will be discussed.

This will be a highly engaging symposium, offering a multitude of fresh perspectives on the current hot topics in schizophrenia management and providing the virtual audience with the opportunity to further benefit from additional insights delivered during our expert faculty discussion.

Educational financial support is provided by Janssen.

Session Icon
Live
Clinical/Therapeutic
Date
Tue, 13.04.2021
Session Time
08:00 - 09:30
Room
Channel 3
Session Description
Proposed by the EPA section on Schizophrenia -The goal of schizophrenia treatment has shifted from symptom reduction and prevention of relapses to functional recovery. However, recovery rates remain very low. Early intervention and identification of predictors of clinical and functional outcome is essential to implement personalized and integrated treatment programs to prevent disability and promote recovery. Stratification of subjects with high-risk status, first-episode and chronic schizophrenia using several predictors of clinical and functional outcome might contribute to early recognition, treatment, rehabilitation and personalized care, promoting prevention of disability, independent leaving, social inclusion and user satisfaction. The symposium will present data in chronic and first-episode patients on predictors of clinical and functional outcome, along with perspectives on personalized and integrated management programs in subjects with schizophrenia and high-risk status.
Session Icon
Live, Section
Date
Mon, 12.04.2021
Session Time
09:30 - 10:00
Room
EPA TV
Session Icon
Live TV
Clinical/Therapeutic
Date
Tue, 13.04.2021
Session Time
17:30 - 19:00
Room
Channel 6
Session Description
The Live Q&A of this session will take place in the Live Sessions auditorium. Please refer to the interactive programme for the exact time and channel.

Cognitive dysfunctions represent a core feature of schizophrenia, are present at any stage of the disease and also in subjects at high risk for psychosis (UHR), and have a significant impact on subject’s psychosocial functioning. Pharmacological treatment is modestly effective on cognitive dimension while there is considerable evidence of the efficacy of cognitive remediation interventions on cognition and functioning of patients with schizophrenia. The Symposium has the aim of updating knowledge about the effectiveness and applicability of cognitive remediation techniques in schizophrenia, with a focus also on new developments and technologies. In particular: - will be presented a systematic review on the factors and ingredients influencing response to cognitive remediation in schizophrenia; will be discussed the applicability of cognitive remediation programs in UHR subjects and their effectiveness in preventing transition to psychosis; - will be discussed the biological signatures and effects of cognitive remediation, as revealed especially by neuroimaging techniques; - finally, a specific lecture will address the present and future developments of cognitive remediation for psychoses, focusing also on programs using new technologies, and discussing promises and limitations of the new approaches in the digital era.

Session Icon
Pre-Recorded with Live Q&A
Date
Tue, 13.04.2021
Session Time
13:00 - 13:30
Room
EPA TV
Session Icon
Live TV
Mental Health Policy
Date
Sun, 11.04.2021
Session Time
12:00 - 13:00
Room
Plenary
Session Icon
Live
Clinical/Therapeutic

Presenter Of 13 Presentations

LIVE - Debate: Should Schizoaffective Disorder be Diagnosed Cross-Sectionally (ICD-11) instead of Longitudinally (DSM-5)? (ID 537) No Topic Needed

Live Q&A

Session Icon
Live, Sessions with Voting
Date
Mon, 12.04.2021
Session Time
19:30 - 21:00
Room
Channel 1
Lecture Time
20:40 - 21:00
Monday, 12 April: Daily Overview (ID 1159) No Topic Needed

Daily Overview

Session Icon
Live TV
Date
Mon, 12.04.2021
Session Time
09:30 - 10:00
Room
EPA TV
Lecture Time
09:30 - 10:00
LIVE - ECP Symposium: Personalised Psychiatry: Hype or Hope? (ID 838) No Topic Needed

Live Q&A

Session Icon
Live, ECP Session
Date
Tue, 13.04.2021
Session Time
10:00 - 11:30
Room
Channel 2
Lecture Time
11:08 - 11:28
Tuesday, 13 April: Midday Roundup (ID 1166) No Topic Needed

Midday Roundup

Session Icon
Live TV
Date
Tue, 13.04.2021
Session Time
13:00 - 13:30
Room
EPA TV
Lecture Time
13:00 - 13:30
LIVE - Symposium: Improving Real-life Functioning in People with Schizophrenia: From Assessment to Integrated Treatment Plans (ID 294) No Topic Needed
Industry Session not Included in the Main Event CME / CPD Credit (ID 1114) No Topic Needed

Welcome and introduction

Session Icon
Live
Date
Sun, 11.04.2021
Session Time
13:30 - 14:30
Room
Industry 1
Lecture Time
13:30 - 13:32
LIVE - Opening Ceremony (ID 1176) No Topic Needed

Opening Ceremony

Session Icon
Live
Date
Sat, 10.04.2021
Session Time
12:00 - 13:00
Room
Plenary
Lecture Time
12:00 - 13:00
Symposium: Cognitive Remediation in Schizophrenia: New Evidences and Future Perspectives in the Digital Era (ID 313) No Topic Needed

Live Q&A

Industry Session not Included in the Main Event CME / CPD Credit (ID 1114) No Topic Needed

LIVE Q&A- Full faculty discussion

Session Icon
Live
Date
Sun, 11.04.2021
Session Time
13:30 - 14:30
Room
Industry 1
Lecture Time
14:08 - 14:28
LIVE - Plenary: Violence Against Women and Mental Health (ID 530) No Topic Needed

Live Q&A

Session Icon
Live
Date
Sun, 11.04.2021
Session Time
12:00 - 13:00
Room
Plenary
Lecture Time
12:40 - 13:00
Industry Session not Included in the Main Event CME / CPD Credit (ID 1114) No Topic Needed

LIVE: Closing remarks

Session Icon
Live
Date
Sun, 11.04.2021
Session Time
13:30 - 14:30
Room
Industry 1
Lecture Time
14:28 - 14:30
LIVE - ECP Symposium: Personalised Psychiatry: Hype or Hope? (ID 838) No Topic Needed

ECP0024 - Precision Medicine in Psychosis: Translating Findings from Research into Clinical Practice

Session Icon
Live, ECP Session
Date
Tue, 13.04.2021
Session Time
10:00 - 11:30
Room
Channel 2
Lecture Time
10:00 - 10:17

ABSTRACT

Abstract Body

Precision medicine is “an emerging approach for treatment and prevention that takes into account each person’s variability in genes, environment, and lifestyle” [1]. The terminology is increasingly used in psychiatry, and especially in research relevant to the prediction of psychosis onset, response to treatment and functional outcome. While this is an important step-forward for the discipline, at this stage it is very important to promote the translation of research findings into clinical practice, as much as possible.

Nowadays the availability of machine learning and artificial intelligence tools, together with advances in data storage and data security, enable the integration of neuroimaging, biological, clinical and cognitive data.

By overcoming current limitations in multiple domain data analysis these tools may lead to the identification of reliable diagnostic, prognostic and therapeutic markers in routine clinical care, as well as to the prediction of clinically meaningful outcomes (e.g., psychosis onset, symptomatic and functional outcome, and treatment response).

Precision medicine in psychiatry is a developing science, deserving further large-scale research, translational approaches and refinement that, hopefully, will soon be an integral part of every-day clinical practice. However, challenges in pursuing this strategy should not be underestimated, and efforts should be made to constantly advocate for more investments in human and financial resources in psychiatry, and to concentrate on the use of widely available and not too expensive and time-consuming methods.

1Toward Precision Medicine. Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press; 2011.

Hide
LIVE - Symposium: Improving Real-life Functioning in People with Schizophrenia: From Assessment to Integrated Treatment Plans (ID 294) No Topic Needed

S0141 - Predictors of Real-life Functioning in Subjects with Schizophrenia: A 4-year Follow-up Study

Session Icon
Live, Section
Date
Tue, 13.04.2021
Session Time
08:00 - 09:30
Room
Channel 3
Lecture Time
08:00 - 08:17

ABSTRACT

Abstract Body

In a cross-sectional study, the Italian Network for Research on Psychoses (INReP) found that variables relevant to the disease, personal resources and social context explain 53.8% of real-life functioning variance in a large sample of community dwelling people with schizophrenia.

In a longitudinal study, the INReP aimed to identify baseline predictors of main domains of real-life functioning, i.e. work skills, interpersonal relationships and everyday life skills, at 4-year follow-up.

We assessed psychopathology, social and non-social cognition, functional capacity, personal resources, and context-related factors, as well as real-life functioning as the main outcome. We used structural equation modeling (SEM) and latent change score (LCS) model to identify predictors of real-life functioning domains at follow-up and changes from baseline in the same domains.

Six-hundred-eighteen subjects took part in the study. Neurocognition predicted everyday life and work skills; avolition predicted interpersonal relationships; positive symptoms work skills, and social cognition work skills and interpersonal functioning. Higher neurocognitive abilities predicted the improvement of everyday life and work skills, as well as of social cognition and functional capacity; better baseline social cognition predicted the improvement of work skills and interpersonal functioning, and better baseline everyday life skills predicted the improvement of work skills.

Several variables which predict important aspects of functional outcome of people with schizophrenia are not routinely assessed and are not systematically targeted by intervention programs in community mental health services. A larger dissemination of practices such as cognitive training and personalized psychosocial interventions should be promoted in mental health care.

Hide